Common use of Service Components Clause in Contracts

Service Components. 4.1 The Provider must provide Opioid Substitution Treatment Services in accordance with the following requirements: (a) the relevant clauses in Schedule 1, in particular clause 9 of Schedule 1; (b) the protocol issued by the Ministry concerning community dispensing of methadone or buprenorphine+naloxone; and (c) any written agreements the Provider may develop with Service Users receiving Opioid Substitution Treatment Services from the Provider in accordance with the Opioid Substitution Treatment New Zealand Practice Guidelines. 4.2 The services the Provider must provide, as part of providing Opioid Substitution Treatment Services, include: (a) providing methadone or buprenorphine+naloxone pursuant to Prescription Forms issued by an opioid substitution treatment service, or by authorised Prescribers; (b) supervising the daily consumption of "consume on premises" methadone or buprenorphine+naloxone doses when the Provider's Premises is open; (c) arranging for the collection of "takeaway doses" for the days when the Provider's Premises is closed, if these have been specifically requested by the Prescriber; (d) ensuring that all methadone or buprenorphine+naloxone Dispensed by the Provider as "takeaway doses" is Dispensed in secure containers and packaging and in accordance with the Provider's written policy; (e) advising and assisting Service Users and Prescribers to enhance compliance with all concurrent prescribed medicines; and (f) developing and implementing a written protocol that sets out how the Provider will liaise with an opioid substitution treatment service and prescribing general practitioners on a regular basis, in a manner appropriate to the needs of the Provider's Service Users, including statements about communications regarding verification of doses, side-effects, complaints about Service Users, and any difficulties arising as a result.

Service Components. 4.1 7.1 The Provider must must, as appropriate, provide Opioid Substitution Treatment Services in accordance with the following requirementsEssential LTC Services to each Service User: (a) the relevant Dispensing Pharmaceuticals and providing Professional Advisory Services in accordance with clauses in Schedule 1, in particular clause 9 3 to 6 of Schedule 1; (b) the protocol issued by the Ministry concerning community dispensing of methadone or buprenorphine+naloxone; and (c) any written agreements medicines reconciliation services, being that the Provider may develop with collects and compares information from Prescribers on the Service Users receiving Opioid Substitution Treatment Services from User’s medicines in order to identify the Provider in accordance with most accurate list of medicines the Opioid Substitution Treatment New Zealand Practice Guidelines. 4.2 The services the Provider must provide, as part of providing Opioid Substitution Treatment Services, include: (a) providing methadone or buprenorphine+naloxone pursuant to Prescription Forms issued by an opioid substitution treatment service, or by authorised Prescribers; (b) supervising the daily consumption of "consume on premises" methadone or buprenorphine+naloxone doses when the Provider's Premises Service User is opentaking; (c) arranging for synchronisation services, being that the collection Provider coordinates the quantities of "takeaway doses" for all the days when Service User’s medications Dispensed to the Provider's Premises is closed, if these have been specifically requested by earliest common date so that the Prescribernext prescription periods can be aligned; (d) ensuring that all methadone or buprenorphine+naloxone Dispensed by reminder services, whereby the Provider as "takeaway doses" provides each Service User with a reminder, in a form agreed with them, about when their next supply of Pharmaceuticals is Dispensed in secure containers and packaging and in accordance with the Provider's written policyto be collected; (e) advising regular screening of a Service User’s compliance with, and assisting Service Users adherence to, their medicines regime and Prescribers to enhance compliance with all concurrent prescribed medicines; andthe provision of medicines alignment services, as further specified (if applicable) in the LTC Services Protocol; (f) developing and implementing a written protocol that sets out how the Provider will liaise Dispensing services, with an opioid substitution treatment service and prescribing general practitioners on a regular basis, in a manner appropriate Dispensing frequency tailored to the needs of the Provider's Service UsersUser and compliant with the requirements of the Pharmaceutical Schedule Rules; and (g) regular engagement, including statements about communications regarding verification as deemed appropriate or agreed, with members of doses, side-effects, complaints about the Service UsersUser’s multidisciplinary care team, and any difficulties arising as in particular, engagement with their key medical practitioner(s), in order to provide the Service User's multidisciplinary care team with information about the Service User’s progress in improving the Service User's management of their medications and compliance and adherence with their medicines regime. 7.2 The Provider must regularly and proactively make contact with the Service User, with clear agreement about mutual expectations and the LTC Services available. 7.3 The LTC Services the Provider provides to each Service User must be supported by appropriate documentation, which the Provider must make available for Te Whatu Ora's inspection and Audit. 7.4 Te Whatu Ora and the Provider acknowledge that it may not be appropriate to provide all of the Essential LTC Services to a resultLTC Service User from the date that Services User is approved to receive LTC Services. 7.5 The Provider must follow the process set out in the LTC Services Protocol for transitioning a Service User on to the appropriate Essential LTC Services. 7.6 Without limiting clause D.22, the Provider must not refer a LTC Service User to another provider for that provider to provide Dispensing Services to the LTC Service User, unless otherwise expressly permitted under this Agreement or if the Provider needs to make an onward referral in an emergency situation in which the Provider is unable to provide urgently needed medication.

Service Components. 4.1 The Provider must provide Opioid Substitution Treatment Services in accordance with the following requirements: (a) the relevant clauses in Schedule 1, in particular clause 9 of Schedule 1; (b) the protocol issued by the Ministry Te Whatu Ora concerning community dispensing of methadone or buprenorphine+naloxone; and (c) any written agreements the Provider may develop with Service Users receiving Opioid Substitution Treatment Services from the Provider in accordance with the Opioid Substitution Treatment New Zealand Practice Guidelines. 4.2 The services the Provider must provide, as part of providing Opioid Substitution Treatment Services, include: (a) providing methadone or buprenorphine+naloxone pursuant to Prescription Forms issued by an opioid substitution treatment service, or by authorised Prescribers; (b) supervising the daily consumption of "consume on premises" methadone or buprenorphine+naloxone doses when the Provider's Premises is open; (c) arranging for the collection of "takeaway doses" for the days when the Provider's Premises is closed, if these have been specifically requested by the Prescriber; (d) ensuring that all methadone or buprenorphine+naloxone Dispensed by the Provider as "takeaway doses" is Dispensed in secure containers and packaging and in accordance with the Provider's written policy; (e) advising and assisting Service Users and Prescribers to enhance compliance with all concurrent prescribed medicines; and (f) developing and implementing a written protocol that sets out how the Provider will liaise with an opioid substitution treatment service and prescribing general practitioners on a regular basis, in a manner appropriate to the needs of the Provider's Service Users, including statements about communications regarding verification of doses, side-effects, complaints about Service Users, and any difficulties arising as a result.

Service Components. 4.1 7.1 The Provider must must, as appropriate, provide Opioid Substitution Treatment Services in accordance with the following requirementsEssential LTC Services to each Service User: (a) the relevant Dispensing Pharmaceuticals and providing Professional Advisory Services in accordance with clauses in Schedule 1, in particular clause 9 3 to 6 of Schedule 1; (b) the protocol issued by the Ministry concerning community dispensing of methadone or buprenorphine+naloxone; and (c) any written agreements medicines reconciliation services, being that the Provider may develop with collects and compares information from Prescribers on the Service Users receiving Opioid Substitution Treatment Services from User’s medicines in order to identify the Provider in accordance with most accurate list of medicines the Opioid Substitution Treatment New Zealand Practice Guidelines. 4.2 The services the Provider must provide, as part of providing Opioid Substitution Treatment Services, include: (a) providing methadone or buprenorphine+naloxone pursuant to Prescription Forms issued by an opioid substitution treatment service, or by authorised Prescribers; (b) supervising the daily consumption of "consume on premises" methadone or buprenorphine+naloxone doses when the Provider's Premises Service User is opentaking; (c) arranging for synchronisation services, being that the collection Provider coordinates the quantities of "takeaway doses" for all the days when Service User’s medications Dispensed to the Provider's Premises is closed, if these have been specifically requested by earliest common date so that the Prescribernext prescription periods can be aligned; (d) ensuring that all methadone or buprenorphine+naloxone Dispensed by reminder services, whereby the Provider as "takeaway doses" provides each Service User with a reminder, in a form agreed with them, about when their next supply of Pharmaceuticals is Dispensed in secure containers and packaging and in accordance with the Provider's written policyto be collected; (e) advising regular screening of a Service User’s compliance with, and assisting Service Users adherence to, their medicines regime and Prescribers to enhance compliance with all concurrent prescribed medicines; andthe provision of medicines alignment services, as further specified (if applicable) in the LTC Services Protocol; (f) developing and implementing a written protocol that sets out how the Provider will liaise Dispensing services, with an opioid substitution treatment service and prescribing general practitioners on a regular basis, in a manner appropriate Dispensing frequency tailored to the needs of the Provider's Service UsersUser and compliant with the requirements of the Pharmaceutical Schedule Rules; and (g) regular engagement, including statements about communications regarding verification as deemed appropriate or agreed, with members of doses, side-effects, complaints about the Service UsersUser’s multidisciplinary care team, and any difficulties arising as in particular, engagement with their key medical practitioner(s), in order to provide the Service User's multidisciplinary care team with information about the Service User’s progress in improving the Service User's management of their medications and compliance and adherence with their medicines regime. 7.2 The Provider must regularly and proactively make contact with the Service User, with clear agreement about mutual expectations and the LTC Services available. 7.3 The LTC Services the Provider provides to each Service User must be supported by appropriate documentation, which the Provider must make available for Health NZ's inspection and Audit. 7.4 Health NZ and the Provider acknowledge that it may not be appropriate to provide all of the Essential LTC Services to a resultLTC Service User from the date that Services User is approved to receive LTC Services. 7.5 The Provider must follow the process set out in the LTC Services Protocol for transitioning a Service User on to the appropriate Essential LTC Services. 7.6 Without limiting clause D.22, the Provider must not refer a LTC Service User to another provider for that provider to provide Dispensing Services to the LTC Service User, unless otherwise expressly permitted under this Agreement or if the Provider needs to make an onward referral in an emergency situation in which the Provider is unable to provide urgently needed medication.

Service Components. 4.1 7.1 The Provider must must, as appropriate, provide Opioid Substitution Treatment Services in accordance with the following requirementsEssential LTC Services to each Service User: (a) the relevant services specified in clauses in 2 to 5 of Schedule 1, in particular clause 9 and clauses 2 to 5 of Schedule 12; (b) the protocol issued by the Ministry concerning community dispensing of methadone or buprenorphine+naloxone; and (c) any written agreements medicines reconciliation services, whereby the Provider may develop with collects and compares information from Prescribers on the Service Users receiving Opioid Substitution Treatment Services from User’s medicines in order to identify the Provider in accordance with most accurate list of medicines the Opioid Substitution Treatment New Zealand Practice Guidelines. 4.2 The services the Provider must provide, as part of providing Opioid Substitution Treatment Services, include: (a) providing methadone or buprenorphine+naloxone pursuant to Prescription Forms issued by an opioid substitution treatment service, or by authorised Prescribers; (b) supervising the daily consumption of "consume on premises" methadone or buprenorphine+naloxone doses when the Provider's Premises Service User is opentaking; (c) arranging for synchronisation services, whereby the collection Provider coordinates the quantities of "takeaway doses" for all the days when Service User’s medications supplied to the Provider's Premises is closed, if these have been specifically requested by earliest common date in order that the Prescribernext prescription periods can be aligned; (d) ensuring that all methadone or buprenorphine+naloxone Dispensed by reminder services, whereby the Provider as "takeaway doses" provides each Service User with a reminder, in a form agreed with them, about when their next supply of Pharmaceuticals is Dispensed in secure containers and packaging and in accordance with the Provider's written policyto be collected; (e) advising regular screening of a Service User’s compliance with, and assisting Service Users adherence to, their medicines regime and Prescribers to enhance compliance with all concurrent prescribed medicines; andthe provision of medicines alignment services, as further specified (if applicable) in the LTC Pharmacist Services Protocol; (f) developing and implementing a written protocol that sets out how the Provider will liaise dispensing services, with an opioid substitution treatment service and prescribing general practitioners on a regular basis, in a manner appropriate dispensing frequency tailored to the needs of the Provider's Service UsersUser and within the Pharmaceutical Schedule Rules; and (g) regular engagement, including statements about communications regarding verification as deemed appropriate or agreed, with members of doses, side-effects, complaints about the Service UsersUser’s multidisciplinary care team, and any difficulties arising as in particular engagement with their key medical practitioner(s), in order to provide them with information about the Service User’s progress in improving their management of their medications and compliance and adherence with their medicines regime. 7.2 The Provider must regularly and proactively make contact with the LTC Service User, with clear agreement about mutual expectations and the LTC Pharmacist Services available. 7.3 The LTC Pharmacist Services the Provider provides to each Service User must be supported by appropriate documentation, which the Provider must make available for the DHB's inspection and Audit. 7.4 The DHB and the Provider acknowledge that it may not be appropriate to provide all of the Essential LTC Services to a resultLTC Service User from the date that Services User is approved to receive LTC Services. 7.5 The Provider must follow the process set out in the LTC Pharmacist Services Protocol for transitioning a Service User on to the appropriate Essential LTC Services. 7.6 Without limiting clause D.22, the Provider must not refer an LTC Service User to another provider for that provider to provide Product Supply Services to the LTC Service User, unless otherwise expressly permitted under this Agreement or if the Provider needs to make an onward referral in an emergency situation in which the Provider is unable to provide urgently needed medication.